These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 24038431)

  • 21. FosPeg® PDT alters the EBV miRNAs and LMP1 protein expression in EBV positive nasopharyngeal carcinoma cells.
    Wu RW; Chu ES; Huang Z; Xu CS; Ip CW; Yow CM
    J Photochem Photobiol B; 2013 Oct; 127():114-22. PubMed ID: 24013466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying genes related to chemosensitivity using support vector machine.
    Bao L
    Methods Mol Med; 2005; 111():233-40. PubMed ID: 15911982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of anticancer drugs and hyperthermia on nasopharyngeal carcinoma cell line in vitro.
    Ha DK; Lau WH
    Cancer Lett; 1989 May; 45(2):103-7. PubMed ID: 2731153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational identification of multi-omic correlates of anticancer therapeutic response.
    Stetson LC; Pearl T; Chen Y; Barnholtz-Sloan JS
    BMC Genomics; 2014; 15 Suppl 7(Suppl 7):S2. PubMed ID: 25573145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network.
    Chen X; Jiang W; Wang Q; Huang T; Wang P; Li Y; Chen X; Lv Y; Li X
    BMC Med Genomics; 2012 Oct; 5():43. PubMed ID: 23031817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential Compounds for Oral Cancer Treatment: Resveratrol, Nimbolide, Lovastatin, Bortezomib, Vorinostat, Berberine, Pterostilbene, Deguelin, Andrographolide, and Colchicine.
    Bundela S; Sharma A; Bisen PS
    PLoS One; 2015; 10(11):e0141719. PubMed ID: 26536350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline/Thioridazine.
    Malard F; Jacquet E; Nhiri N; Sizun C; Chabrier A; Messaoudi S; Dejeu J; Betzi S; Zhang X; Thureau A; Lescop E
    ChemMedChem; 2022 Jan; 17(1):e202100528. PubMed ID: 34472703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new approach for prediction of tumor sensitivity to targeted drugs based on functional data.
    Berlow N; Davis LE; Cantor EL; Séguin B; Keller C; Pal R
    BMC Bioinformatics; 2013 Jul; 14():239. PubMed ID: 23890326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells.
    Lan MY; Hsu YB; Lan MC; Chen JP; Lu YJ
    Int J Nanomedicine; 2020; 15():7569-7582. PubMed ID: 33116488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Podoplanin, a Potential Therapeutic Target for Nasopharyngeal Carcinoma.
    Hsu YB; Huang CF; Lin KT; Kuo YL; Lan MC; Lan MY
    Biomed Res Int; 2019; 2019():7457013. PubMed ID: 31321241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma.
    Hsu YB; Lan MC; Kuo YL; Huang CF; Lan MY
    Invest New Drugs; 2020 Apr; 38(2):264-273. PubMed ID: 30993588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Big Data in Head and Neck Cancer.
    Resteghini C; Trama A; Borgonovi E; Hosni H; Corrao G; Orlandi E; Calareso G; De Cecco L; Piazza C; Mainardi L; Licitra L
    Curr Treat Options Oncol; 2018 Oct; 19(12):62. PubMed ID: 30361937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics.
    Hernandez JJ; Pryszlak M; Smith L; Yanchus C; Kurji N; Shahani VM; Molinski SV
    Front Oncol; 2017; 7():273. PubMed ID: 29184849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo.
    Fang EF; Zhang CZ; Ng TB; Wong JH; Pan WL; Ye XJ; Chan YS; Fong WP
    Cancer Prev Res (Phila); 2012 Jan; 5(1):109-21. PubMed ID: 21933914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125a-5p.
    Gao W; Chan JY; Wong TS
    Clin Sci (Lond); 2014 Nov; 127(9):571-9. PubMed ID: 24896104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From NPC therapeutic target identification to potential treatment strategy.
    Lan MY; Chen CL; Lin KT; Lee SA; Yang WL; Hsu CN; Wu JC; Ho CY; Lin JC; Huang CY
    Mol Cancer Ther; 2010 Sep; 9(9):2511-23. PubMed ID: 20716640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using computational strategies to predict potential drugs for nasopharyngeal carcinoma.
    Lan MY; Yang WL; Lin KT; Lin JC; Shann YJ; Ho CY; Huang CY
    Head Neck; 2014 Oct; 36(10):1398-407. PubMed ID: 24038431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result.
    Yang WL; Lee YE; Chen MH; Chao KM; Huang CY
    Gene; 2013 Apr; 518(1):201-8. PubMed ID: 23220021
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.